Abstract
Summary
We performed a systematic review and meta-analysis of randomized clinical trials. Early administration of bisphosphonates (BPs) after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.
Introduction
Bisphosphonates (BPs) are widely used in the prophylaxis and treatment of osteoporosis. However, early administration of BPs after surgical repair of a fracture may limit the reserve capacity of bone to heal. The aim of this review and meta-analysis was to analyze the benefits and adverse effects of early administration of BPs and give recommendations regarding when BPs should be utilized.
Methods
We identified randomized controlled trials comparing the early administration of BPs to placebo, delayed BP treatment, or no therapy in adult patients after surgery. The search was performed in PubMed, the Cochrane Library, and Embase.
Results
Ten studies with 2888 patients were included. Four trials used alendronate, three trials used zoledronic, two trials used risedronate, and one trial used etidronate. Early administration of BPs was considered less than 3 months after surgery. Patients treated with BP therapy had no significant differences in radiological fracture healing times compared with patients in the control group (mean difference [MD] 0.47, 95 % confidence interval [CI] −2.75 to 3.69). There were also no significant differences in the rate of delay or nonunion of fracture healing (odds ratio [OR] 0.98, 95 % CI 0.64 to 1.50). However, the bone mineral density (BMD) of total hips did significantly improve after 12 months of treatment with BPs. And most bone turnover markers of patients in the study group were significantly decreased.
Conclusions
Early administration of BPs after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, according to the changes in BMD and bone turnover markers, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.
Similar content being viewed by others
References
Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47(2):169–180. doi:10.1016/j.bone.2010.05.019
Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS (2010) Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol 72(2):161–168. doi:10.1111/j.1365-2265.2009.03581.x
Ha YC, Cho MR, Park KH, Kim SY, Koo KH (2010) Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 468(12):3393–3398. doi:10.1007/s11999-010-1583-2
Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ (2011) The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 71(1):186–190. doi:10.1097/TA.0b013e31821957e3
von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS (2005) Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26(34):6941–6949. doi:10.1016/j.biomaterials.2005.04.059
Li H, Xie H, Liu W, Hu R, Huang B, Tan YF, Xu K, Sheng ZF, Zhou HD, Wu XP, Luo XH (2009) A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 119(12):3666–3677. doi:10.1172/JCI39832
Hu R, Liu W, Li H, Yang L, Chen C, Xia ZY, Guo LJ, Xie H, Zhou HD, Wu XP, Luo XH (2011) A Runx2/miR-3960/miR-2861 regulatory feedback loop during mouse osteoblast differentiation. J Biol Chem 286(14):12328–12339. doi:10.1074/jbc.M110.176099
Shah A, Ahmad A (2011) Role of microRNA in mesenchymal stem cells differentiation into osteoblasts. Exp Hematol 39(6):608–616. doi:10.1016/j.exphem.2011.01.011
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294–1301. doi:10.1210/jc.2004-0952
Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 17(12):2237–2246. doi:10.1359/jbmr.2002.17.12.2237
Matos MA, Tannuri U, Guarniero R (2010) The effect of zoledronate during bone healing. J Orthop Traumatol: Off J Italian Soc Orthop Traumatol 11(1):7–12. doi:10.1007/s10195-010-0083-1
Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 14(6):969–979. doi:10.1359/jbmr.1999.14.6.969
Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H (2001) Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 16(3):429–436. doi:10.1359/jbmr.2001.16.3.429
Bauss F, Schenk RK, Hort S, Muller-Beckmann B, Sponer G (2004) New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 50(1):25–34. doi:10.1016/j.vascn.2003.11.003
Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res: Off J Am Soc Bone Miner Res 19(11):1779–1786. doi:10.1359/JBMR.040814
Greiner SH, Wildemann B, Back DA, Alidoust M, Schwabe P, Haas NP, Schmidmaier G (2008) Local application of zoledronic acid incorporated in a poly(D, L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop 79(5):717–725. doi:10.1080/17453670810016768
Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML (2009) Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg 34(4):595–602. doi:10.1016/j.jhsa.2008.12.011
Amanat N, Brown R, Bilston LE, Little DG (2005) A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res: Off Publ Orthop Res Soc 23(5):1029–1034. doi:10.1016/j.orthres.2005.03.004
Goodship AE, Walker PC, McNally D, Chambers T, Green JR (1994) Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 5(Suppl 7):S53–S55
Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N (2005) Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res: Off J Am Soc Bone Miner Res 20(11):2044–2052. doi:10.1359/JBMR.050712
Bransford R, Goergens E, Briody J, Amanat N, Cree A, Little D (2007) Effect of zoledronic acid in an L6-L7 rabbit spine fusion model. Eur Spine J: Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Section Cervical Spine Res Soc 16(4):557–562. doi:10.1007/s00586-006-0212-y
Grady MK, Watson JT, Cannada LK (2012) Treatment of femoral fracture nonunion after long-term bisphosphonate use. Orthopedics 35(6):e991–e995. doi:10.3928/01477447-20120525-51
Benlebna F, El AF, Boumediene ZB, El KM, Medghar S, Djaroud Z (2011) Delay of consolidation and bisphosphonates: two cases. Ann Phys Rehabil Med 54:e182–e183
Czerwinski E, Osieleniec J, Loranc A (2011) Delayed union after atypical subtrochanteric fracture under alendronate treatment: case report. Osteoporos Int 22:S220
Li C, Wang HR, Li XL, Zhou XG, Dong J (2012) The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery. Acta Neurochir (Wien) 154(4):731–738. doi:10.1007/s00701-012-1283-7
Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C (2011) Association between timing of zoledronic acid infusion and hip fracture healing, vol 22. Osteoporos Int. doi:10.1007/s00198-010-1473-1
Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, Trial HRF (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809. doi:10.1056/NEJMoa074941
Ng AJ, Yue B, Joseph S, Richardson M (2014) Delayed/non-union of upper limb fractures with bisphosphonates: systematic review and recommendations. ANZ J Surg 84(4):218–224. doi:10.1111/ans.12536
Uchiyama S, Itsubo T, Nakamura K, Fujinaga Y, Sato N, Imaeda T, Kadoya M, Kato H (2013) Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. Bone Joint J 95-B(11):1544–1550. doi:10.1302/0301-620x.95b11.31652
Kim TY, Ha YC, Kang BJ, Lee YK, Koo KH (2012) Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg Br Vol 94:956–960. doi:10.1302/0301-620x.94b7.29079
Gong HS, Song CH, Lee YH, Rhee SH, Lee HJ, Baek GH (2012) Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures, vol 94. J Bone Joint Surg Am Vol. doi:10.2106/jbjs.k.01434
Harding AK, W-Dahl A, Geijer M, Toksvig-Larsen S, Tagil M (2011) A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies. Acta Orthop 82(4):465–470. doi:10.3109/17453674.2011.594231
Harding AK, Toksvig-Larsen S, Tagil M, W-Dahl A (2010) A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients. Bone 46(3):649–654. doi:10.1016/j.bone.2009.10.040
Cecilia D, Jodar E, Fernandez C, Resines C, Hawkins F (2009) Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int 20(6):903–910. doi:10.1007/s00198-008-0767-z
Altintas F, Ozkut AT, Beyzadeoglu T, Eren A, Guven M (2007) The effect of risedronate treatment on bone turnover markers in patients with hip fracture. Acta Orthop Traumatol Turc 41(2):132–135
Sato Y, Kanoko T, Yasuda H, Satoh K, Iwamoto J (2004) Beneficial effect of etidronate therapy in immobilized hip fracture patients. Am J Phys Med Rehabil 83(4):298–303. doi:10.1097/01.PHM.0000122877.28631.23
van der Poest CE, van Engeland M, Ader H, Roos JC, Patka P, Lips P (2002) Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res 17(12):2247–2255. doi:10.1359/jbmr.2002.17.12.2247
Boonen S, Orwoll E, Magaziner J, Colon-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW (2011) Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59(11):2084–2090. doi:10.1111/j.1532-5415.2011.03666.x
Adachi JD, Lyles K, Boonen S, Colon-Emeric C, Hyldstrup L, Nordsletten L, Pieper C, Recknor C, Su G, Bucci-Rechtweg C, Magaziner J (2011) Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-Recurrent Fracture Trial. Calcif Tissue Int 89(6):427–433. doi:10.1007/s00223-011-9543-8
Colon-Emeric CS, Lyles KW, Su G, Pieper CF, Magaziner JS, Adachi JD, Bucci-Rechtweg CM, Haentjens P, Boonen S (2011) Clinical risk factors for recurrent fracture after hip fracture: a prospective study. Calcif Tissue Int 88(5):425–431. doi:10.1007/s00223-011-9474-4
Adachi JD, Lyles KW, Colon-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS (2011) Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int 22(9):2539–2549. doi:10.1007/s00198-010-1514-9
Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C (2011) Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 22(8):2329–2336. doi:10.1007/s00198-010-1473-1
Boonen S, Black DM, Colon-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58(2):292–299. doi:10.1111/j.1532-5415.2009.02673.x
Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25(1):91–97. doi:10.1359/jbmr.090704
Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308–1313. doi:10.1359/jbmr.090209
Colon-Emeric CS, Caminis J, Suh TT, Pieper CF, Janning C, Magaziner J, Adachi J, Rosario-Jansen T, Mesenbrink P, Horowitz ZD, Lyles KW (2004) The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin 20(6):903–910. doi:10.1185/030079904125003683
Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S (2007) Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am 89(1):96–101. doi:10.2106/jbjs.f.00484
Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272–2282. doi:10.1210/jc.2012-1027
Goldhahn J, Feron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R, Dere W, Mitlak B, Tsouderos Y, Boonen S (2012) Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 90(5):343–353. doi:10.1007/s00223-012-9587-4
Jorgensen NR, Schwarz P (2011) Effects of anti-osteoporosis medications on fracture healing. Curr Osteoporos Rep 9(3):149–155. doi:10.1007/s11914-011-0065-0
Miller PD (2005) Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 3(3):103–110. doi:10.1007/s11914-005-0018-6
Coates P (2013) Bone turnover markers. Aust Fam Physician 42(5):285–287
Klemens AS, McMillin DR (1990) New method for removing type 2 copper from Rhus laccase. J Inorg Biochem 38(2):107–115. doi:10.1016/0162-0134(90)84019-L
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Yi-Ting Li and Hai-Feng Cai contributed equally to this work.
Rights and permissions
About this article
Cite this article
Li, YT., Cai, HF. & Zhang, ZL. Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 26, 431–441 (2015). https://doi.org/10.1007/s00198-014-2903-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-014-2903-2